AzTrials
AzTrials

Neutrophil Extracellular Traps FormationNCT06441708

Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.

An observational study of Neutrophil Extracellular Traps Formation, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record

Search all trials

Trial summary

Aim of the work: To determine the killing ability of neutrophils to ATCC 27853, carbapenem-resistant P. aeruginosa. To compare between the ability of ATCC 27853, carbapenem-resistant P. aeruginosa to induce NETs formation. To quantify NETS formation in response to PMA, ATCC 27853, carbapenem-resistant P. Read more about this study

Who is it for?
Any age
Conditions the study is for
Neutrophil Extracellular Traps Formation
How many people
50 participants
Where
No sites listed yet
Study dates
1 Jun 2024to 1 Jul 2025
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Clinical isolates from different clinical samples including urine, blood, sputum, wound

Who may be able to join

  • isolates will be isolated from different clinical samples including wound respiratory tract urine and blood. _carbapenem-resistant P. aeruginosa isolates.

Who cannot join

  • _carbapenem-sensitive P. aeruginosa isolates.

Trial locations and contacts

No sites are listed yet.

Noura Samir Hussein, Assistant lecturer contact

00201002606302

nourasamir@aun.edu.eg

About this study

Official title: Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa Isolated From Hospital Acquired Infections in Assiut University Hospitals

Aim of the work:

To determine the killing ability of neutrophils to ATCC 27853, carbapenem-resistant P. aeruginosa.

To compare between the ability of ATCC 27853, carbapenem-resistant P. aeruginosa to induce NETs formation.

To quantify NETS formation in response to PMA, ATCC 27853, carbapenem-resistant P. aeruginosa using immunofluorescence.

To determine the killing ability of NETs on ATCC 27853, carbapenem-resistant P. aeruginosa.

Read the detailed description

Pseudomonas aeruginosa is one of the most common pathogens in healthcare-associated infections worldwide, causing ventilator-associated pneumonia, urinary tract infections in patients with long-term urinary catheterization, wound infections, bloodstream infections, and otitis (reynolds and kollef, 2021).

Carbapenem-resistant-P. aeruginosa infection is a prominent disease connected to healthcare due to multiple mechanisms, such as target alteration, active efflux, decreased permeability, and enzyme degradation (Tenover et al., 2022).

Neutrophils are the most prominent cellular component of the innate immune response and are essential for defense against bacterial infections (Chapple et al., 2023).

In addition to traditional antimicrobial processes of neutrophils, a unique web-like structure, is termed neutrophil extracellular traps (NETs), formed and released by highly active neutrophils. NETs consist of extracellular deoxyribonucleic acid (eDNA) filaments coated with histones and neutrophil granule proteins such as Myeloperoxidase (MPO), neutrophil elastase (NE), lactoferrin, cathepsins, calprotectin, LL-37, and defensin (Papayannopoulos, 2018).

MPO and NE are key components of NETs and play roles in their function and structure. MPO, a heme protein primarily stored in the granules of neutrophils, contributes significantly to microbial killing within NETs. It catalyzes the production of hypochlorous acid from hydrogen peroxide and chloride ions, a reaction central to the antimicrobial properties of NETs. NE, another granule protein extends to modulating inflammation and immune response (Islam et al., 2023).

The role of NETs during bacterial infection is not completely clear. It promoted the clearance of bacteria by facilitating the entrapping and killing of these pathogens, However, it has been described that the granular proteins released within the NETs act mainly as a regulator of inflammation due to the action on different cytokines, rather than as a bactericidal mechanism (Clancy, 2018).

  1. aeruginosa-mediated factors contribute to the NETosis and release of a large amount of NETs. However, sequestration of P. aeruginosa by traps does not lead to the complete destruction of bacteria, but, it promotes their microcolonization, aggregation, and finally biofilm formation, leading to the formation of higher resistance to NETs-mediated bactericidal activity (Rahman and Gadjeva, 2014).

Neutrophils formed a NET-barrier to keep bacteria outside in the form of biofilm and prevent their spread to the brain. Thus, the NET formation is probably a useful mechanism for protecting the brain against infections through the ocular route (Thanabalasuriar et al., 2019).

Being tested
No intervention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No interventionOther

    No intervention on patient

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quantitification of neutrophils extracellular traps by immunofluroscrnce

    Quantitification of neutrophils extracellular traps by indirect immunofluroscrnce

    Measured: Three months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2024
  2. Study start1 Jun 2024 (estimated)
  3. Primary completion1 Jun 2025 (estimated)
  4. Study completion1 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06441708
Sponsor's protocol ID
Pseudomonas aeruginosa
Status last verified
Jun 2024
First submitted
29 May 2024
Last updated
4 Jun 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in